@article{Leerasiri_Rattanachaiyanont_Angsuwathana_Techatraisak_Tanmahasamut_Tanphatthana_2006, title={Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study}, volume={58}, url={https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/245823}, abstractNote={<p><strong>Objective: </strong>A randomized control study to compare the effectiveness and the safety of very low dose oral contraceptive (OC) with progestin for the treatment of endometrial hyperplasia.<br><strong>Methods: </strong>Ten patients with non-atypical endometrial hyperplasia who did not have contraindications for OC were randomized to receive either OC (Mercilon®) or progestin (Medroxy progesterone acetate: MPA) for 6 months at the Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital. Their main measured outcomes were endometrial histopathology and adverse events.<br><strong>Results: </strong>Sixty percent (3 of 5) of the progestin group and 80% (4 of 5) of the OC group completed the 6-month therapy. All of them had normal endometrium by the end of the 6<sup>th</sup> cycle of treatment. Two cases in the progestin group and one case in the OC group withdrew from the study by the end of 1<sup>st</sup> cycle of treatment. No serious adverse event was detected during the study period.<br><strong>Conclusion: </strong>OC may be as effective and safe as progestin for the treatment of non-atypical endometrial hyperplasia.</p>}, number={5}, journal={Siriraj Medical Journal}, author={Leerasiri, Pichai and Rattanachaiyanont, Manee and Angsuwathana, Surasak and Techatraisak, Kitirat and Tanmahasamut, Prasong and Tanphatthana, Suchada}, year={2006}, month={May}, pages={795–798} }